Issue

Vol. 64 No. 6: Advances in mechanism and treatment strategy of cancer

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Flavored Guilu Erxian decoction inhibits the injury of human bone marrow mesenchymal stem cells induced by cisplatin

https://doi.org/10.14715/cmb/2018.64.6.11
Bin Ke
Department of Traditional Chinese Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Lin Shi
Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Zhaozhong Xu
Department of Emergency, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Gang Wu
Department of Cancer Center, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Yuxin Gong
Department of Respiratory Diseases, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Lixia Zhu
Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Yanjing Wang
Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Huailiang Ouyang
Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Xilong Wang
Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China

Corresponding Author(s) : Lin Shi

Shilin293@163.com

Cellular and Molecular Biology, Vol. 64 No. 6: Advances in mechanism and treatment strategy of cancer

Abstract

To examine the exact role of flavored Guilu Erxian decoction, a Traditional Chinese Medicine (TCM) in the treatment of cisplatin-induced side-effects in bone marrow mesenchymal stem cells (BM-MSCs). BM-MSCs were isolated from bone marrow collected from SD rats and identified by flow cytometry. Cells were cultivated in MEM alpha medium containing 5% (TCM-L), 10% (TCM-M) and 20% (TCM-H) dosages of flavored Guilu Erxian decoction with or without cisplatin. Cell viability was determined through CCK-8 and thymidine analog 5-ethynyl-2"²-deoxyuridine (EdU) staining assay. Flow cytometry was used to determine cell cycle and apoptosis. The expression of p21 and cleaved-caspase-3 were examined using Western blot assay. The PI3K-AKT-mTOR pathway associated proteins, including p-PI3K, p-AKT and p-mTOR, were also examined by Western blot assay. CCK-8 and EdU staining assay demonstrated that cisplatin could inhibit cell proliferation in BM-MSCs in a dose and time dependent manner. Further, cisplatin could induce apoptosis through increasing G0/G1 cell cycle arrest, p21 and cleaved-caspase-3 expression. However, these phenomena would be significantly alleviated when adding the serum containing flavored Guilu Erxian decoction. Furthermore, the PI3K-AKT-mTOR pathway activation could be inhibited by cisplatin in BM-MSCs, while flavored Guilu Erxian decoction treatment successfully abrogated this effect. Combination of flavored Guilu Erxian decoction and cisplatin could reduce the damage to BM-MSCs. This indicates that the flavored Guilu Erxian decoction can enhance the possibility of BM-MSCs repairing and rehabilitating the normal function of injured tissues induced by cisplatin, which could provide a new direction for therapeutic applications.

Keywords

Flavored Guilu Erxian decoction Traditional Chinese Medicine (TCM) Cisplatin BM-MSCs Proliferation Apoptosis.
Ke, B., Shi, L., Xu, Z., Wu, G., Gong, Y., Zhu, L., Wang, Y., Ouyang, H., & Wang, X. (2018). Flavored Guilu Erxian decoction inhibits the injury of human bone marrow mesenchymal stem cells induced by cisplatin. Cellular and Molecular Biology, 64(6), 58–64. https://doi.org/10.14715/cmb/2018.64.6.11
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Kodama A WH, Tanaka R, et al. Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity. Biochimica et Biophysica Acta 2014; 1840: 1152-1162.
  2. Lebwohl D CR. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. European Journal of Cancer 1998; 34(10): 1522 - 1534.
  3. Shiraishi F CL, Truong L, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. American Journal of Physiology: Renal Physiology 2000; 278(5): F726- F736.
  4. Abolfazl Avan TJP, et al. Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future. Oncologist 2015; 20(4 ): 411–432.
  5. Steyger. TKaPS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicology Letters 2015; 237: 219-227.
  6. Kunter U RS, Djuric Z, et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17(8): 2202–2212.
  7. A. C. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011; 71: 3–10.
  8. Galluzzi L VI, Michels J, et al Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5: e1257.
  9. Agung M. OM, Yanada S., et al. Mobilization of bone marrow-derived mesenchymal stem cells into the injured tissues after intraarticular injection and their contribution to tissue regeneration. Knee Surg Sports Traumatol Arthrosc 2006; 14: 1307–1314.
  10. Ohishi M. SE. Bone marrow mesenchymal stem cells. J Cell Biochem 2010; 109: 277–282.
  11. Kucerova L SS. Tumor microenvironment and the role of mesenchymal stromal cells. Neoplasma 2013; 60(1): 1–10.
  12. Brooke G CM, Blair C, et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007; 18: 846–858
  13. DJ. P. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009; 17: 939–946
  14. Uccelli A ML, and Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726–736.
  15. Goldstein RH RM, Anderson K, et al. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 2010; 70: 10044–10050.
  16. Chaturvedi P GD, Wong CC, et al. Hypoxiainducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 2013; 123: 189–205.
  17. Torsvik A BR. Mesenchymal stem cell signaling in cancer progression. Cancer Treat Rev 2013; 39: 180-188.
  18. Abd-Allah S.H. SSM, Pasha H.F., et al. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. Cytotherapy 2013; 15: 64–75.
  19. Kilic S. PF, Ozogul C.,et al. Protection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty. Gynecol Endocrinol 2013; 30: 135–140.
  20. Herrera MB BB, Bruno S, et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004; 14(6): 1035–1041.
  21. Eisenberg DM DR, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. Journal of the American Medical Association 1998; 280(18): 1569–1575.
  22. K. C. Progress in traditional Chinese medicine. Trends Pharmacol Sci 1995; 16: 182–187.
  23. J. Q. Traditional medicine: a culture in the balance. Nature 2007; 448: 126–128.
  24. D. N. The new face of traditional Chinese medicine. Science 2003; 299: 188–190.
  25. Dominici M LBK, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-317.
  26. A. Kodama HW, R. Tanaka et al. Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephro-toxicity. Biochimica et Biophysica Acta 2014; 1840: 1152-1162.
  27. Johnson SM GP, Rampy BA, et al. Novel expression patterns of pi3k/AKT/mtor signaling pathway components in colorectal cancer. J Am Coll Surg 2010; 210: 767–768.
  28. King D YD, Bryant HE. Pi3king the lock: Targeting the pi3k/AKT/mtor pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol 2015; 37: 245–251.
  29. Ou Y. ZD, Wu N., et al. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1. Gene 2015; 572(1): 116–122.
  30. Agarwal R. KSB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
  31. Ning Yu YXCW. Bu-Zhong-Yi-Qi Decoction, the Water Extract of Chinese Traditional Herbal Medicine, Enhances Cisplatin Cytotoxicity in A549/DDP Cells through Induction of Apoptosis and Autophagy Biomed Res Int 2017; 2017: 3692797.
  32. Zhi-Ying Teng X-LC, Xue-Ting Cai, et al. Ancient Chinese Formula Qiong-Yu-Gao Protects Against Cisplatin-Induced Nephrotoxicity Without Reducing Anti-tumor Activity. Sci Rep 2015; 5: 15592.
  33. J. S. Immune regulation by mesenchymal stem cells:two sides to the coin. Tissue Antigens 2007; 69(1): 1-9.
  34. Guo J.Q. GX, Lin Z.J., et al. BMSCs reduce rat granulosa cell apoptosis induced by cisplatin and perimenopause. BMC Cell Biol 2013; 14: 1–9.
  35. Santos N. CC, Martins N., et al. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 2007; 81: 495-504.
  36. Z.H. S. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
  37. Fu X HY, Xie C, et al. Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian damage. Cytotherapy 2008; 10: 353–363.
  38. L. K. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573–584.
  39. Zangen R RE, Sidransky D. DeltaNp63α levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4: 1313–1315.
  40. Zhang R NY, Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett 2010; 192(2): 108-114.
  41. ZH S. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22(47): 7265-7279.
  42. Kumar S YC, Tchounwou PB. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res 2014 33: 42.
  43. Yedjou CG TP. Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. Mol Cell Biochem 2009 331: 207-214.
  44. Tchounwou SKPB. Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells. Oncotarget 2015; 6(38): 40734-40746.
  45. Jordan P C-FM. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57: 1229-1235.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 853 Download : 449